Preferred Label : janus kinases;

MeSH definition : A family of intracellular tyrosine kinases that participate in the signaling cascade of cytokines by associating with specific CYTOKINE RECEPTORS. They act upon STAT TRANSCRIPTION FACTORS in signaling pathway referred to as the JAK/STAT pathway. The name Janus kinase refers to the fact the proteins have two phosphate-transferring domains.;

MeSH synonym : kinases, janus; JAK Kinases; kinases, jak; Janus Kinase; Kinase, Janus;

CISMeF synonym : EC 2.7.1.112;

Registry Number MeSH : EC 2.7.10.2;

Wikipedia link : https://en.wikipedia.org/wiki/Janus kinases;

Is substance : O;

UNII : EC 2.7.10.2;

Details


Main resources

You can consult :

A family of intracellular tyrosine kinases that participate in the signaling cascade of cytokines by associating with specific CYTOKINE RECEPTORS. They act upon STAT TRANSCRIPTION FACTORS in signaling pathway referred to as the JAK/STAT pathway. The name Janus kinase refers to the fact the proteins have two phosphate-transferring domains.

https://www.inesss.qc.ca/fileadmin/doc/INESSS/COVID-19/COVID-19_JAKi.pdf
2021
Canada
COVID-19
guidelines for drug use
janus kinases
Janus Kinase Inhibitors
pneumonia, viral
coronavirus infections
pandemics

---
http://www.cri-net.com/ckfinder/userfiles/files/fiches-pratiques/JAKi-juillet2018/JAK_17_Connectivites.pdf
2018
France
guideline
Janus Kinase Inhibitors
janus kinases
collagen disease, nos
collagen diseases

---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-BCR-ABL-Imatinib-Dasatinib-Nilotinib-Bosutinib-Ponatinib-Medicament-ciblant-JAK-Ruxolitinib-Anticancereux-par-voie-orale-informer-prevenir-et-gerer-leurs-effets-indesirables
2016
false
false
false
France
French
practice guideline
antineoplastic agents
administration, oral
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
information dissemination
patient education as topic
drug interactions
Dasatinib
Imatinib Mesylate
fusion proteins, bcr-abl
protein kinase inhibitors
dasatinib
imatinib
nilotinib
nilotinib
bosutinib
ponatinib
ruxolitinib
janus kinases
ponatinib
ruxolitinib
bosutinib
continuity of patient care
pregnancy
Tyrosine Kinase Inhibitors
nilotinib
ruxolitinib
aniline compounds
nitriles
quinolines
imidazoles
pyridazines
pyrimidines
pyrazoles

---
http://www.e-cancer.fr/content/download/126025/1524695/file/Médicaments%20ciblant%20BCR-ABL.pdf
2015
false
false
false
France
French
practice guideline
guidelines for drug use
administration, oral
antineoplastic agents
Drug-Related side effects and adverse reactions
imatinib
dasatinib
nilotinib
nilotinib
bosutinib
bosutinib
ponatinib
ponatinib
protein kinase inhibitors
ruxolitinib
ruxolitinib
janus kinases
information dissemination
continuity of patient care
hospital-physician relations
hospital-patient relations
physician-patient relations
drug interactions
pregnancy
protein-tyrosine kinases
Tyrosine Kinase Inhibitor
Dasatinib
Imatinib Mesylate
Tyrosine Kinase Inhibitors
nilotinib
ruxolitinib
pyrazoles
aniline compounds
nitriles
quinolines
imidazoles
pyridazines

---
Nous contacter.
26/04/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.